Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Key Highlights
- ➤$30 million private placement completed, with potential proceeds up to $85 million
- ➤Third-quarter sales fell 44.5% to $404,597 on international FemBloc order timing
- ➤Third-quarter net loss widened to $4,564,815, or $0.53 per share
- ➤FINALE pivotal-trial enrolling sites doubled to twelve supporting U.S. approval
- ➤Cash and equivalents reached approximately $23.9 million at September 30, 2026
Expert Statements
Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys
“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys. With U.S. fertility rates at historic lows, there is an urgent need to bring treatment to the OB/GYN office, where women already seek care. Our portfolio enables these physicians to offer a complete pathway from diagnostics through first-step treatment, supported by partnerships that simplify access to patient financing and fertility medications. Since closing the financing, we have been successfully recruiting commercial professionals with deep OB/GYN expertise and established relationships. Healthcare system partnerships and initial sales achieved with limited resources demonstrate the commercial potential of our comprehensive fertility portfolio. These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”
ATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.
Corporate Highlights from 3Q 2026 to date * Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed(®) fertility portfolio to OB/GYNs, and to fund the FemBloc(®) pivotal trial to support U.S. approval. * Highlights for the FemaSeed Fertility Portfolio (Diagnostics: FemVue(®) for her and SpermVue(TM) for him; first-step treatment: FemaSeed and FemSperm(®)): * Announced a partnership with both UNC Health and Minnesota Women’s Care to introduce the entire portfolio across its OB/GYN practice locations. * Announced a partnership with CapexMD to expand patient access through financing solutions and SandsRx Pharmacy for medications to support treatment timing.
Get started
Create a free account to read the full story.